Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy.

Abstract

INTRODUCTION:

Factors predicting response to adjuvant chemotherapy (AC) are required to identify patients who will most benefit from it. The aim of this study was to evaluate the impact of carcinoma in situ (CIS) at radical cystectomy (RC) on recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS) of patients treated by AC.

MATERIALS AND METHODS:

A single-center retrospective study was performed on patients who received AC after RC without pre-RC chemotherapy or trimodal therapy.

RESULTS:

Among the 150 patients analyzed, 52,7% had CIS on the RC specimens. Baseline characteristics were not significantly different between the CIS negative and positive groups. Most patients received a cisplatin-based AC (74%). The median follow-up of the cohort was 36,4 months. The presence of CIS was not significantly associated to disease-recurrence (OR=0.67; 95%CI=0.35-1.29; P=0.23), cancer related death (OR=0.70; 95%CI=0.36-1.33; P=0.27) or death by any cause (OR=0.80; 95%CI=0.42-1.52; P=0.50). The presence of CIS had no significant impact on RFS (HR=0.86; 95%CI=0.56-1.33; P=0.49), CSS (HR=0.85; 95%CI=0.53-1.36; P=0.50) or OS (HR=0.93; 95%CI=0.60-1.45; P=0.74).

CONCLUSION:

The presence of CIS on RC specimens did not have an impact on survival of patients treated by AC. CIS could be evaluated as a prognostic factor of response to novel adjuvant regimens such as immunotherapy.

• Authors: Y Soorojebally, L Surlemont, Y Neuzillet, T Lebret
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 32 Issue 1 Pg. 53-60 (Jan 2022) ISSN: 1166-7087 [Print] France
• PMID: 34756696 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Topics

• Carcinoma in Situ (pathology)
• Chemotherapy, Adjuvant
• Cystectomy
• Humans
• Neoplasm Recurrence, Local
• Neoplasm Staging
• Retrospective Studies
• Treatment Outcome
• Urinary Bladder Neoplasms (pathology)